Meir Schechter, Stephen D Wiviott, Itamar Raz, Erica L Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A Murphy, Thomas A Zelniker, Martin Fredriksson, Peter A Johansson, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S Sabatine, Ofri Mosenzon
BACKGROUND: In people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease...
March 3, 2023: Lancet Diabetes & Endocrinology